Skip to content

The efficacy of Jiedu Granules in patients with advanced hepatocellular carcinoma: a cohort study

The efficacy of Jiedu Granules in patients with advanced hepatocellular carcinoma: a cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16008002
Enrollment
Unknown
Registered
2016-01-16
Start date
2013-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

TCM group:Jie-du granule

Sponsors

Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male or female, aged older than 18years; 2. Diagnosed with hepatocellular carcinoma according to the Guideline of Primary Liver Cancer published by the Ministry of Health of China; 3. Stage is C according to the BCLC staging classification; 4. Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2.

Exclusion criteria

Exclusion criteria: 1. Received chemotherapy or radiotherapy or local therapies such as TACE, RF within 4 weeks; 2. Serum total bilirubin higher than 3 times of upper limit of normal value or ascites; 3. Serum creatinine higher than 2 times of upper limit of normal value; 4. Gastrointestinal hemorrhage within 4 weeks; 5. Have other malignant tumors; 6. Severe infection; 7. Pregnancy.

Design outcomes

Primary

MeasureTime frame
1 year survival;

Secondary

MeasureTime frame
Overall survival;Progression-free survival;safety index;

Countries

China

Contacts

Public ContactXiaofeng Zhai
zhxfch@163.com+86 021 31161950

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026